GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sailong Pharmaceutical Group Co Ltd (SZSE:002898) » Definitions » Cash And Cash Equivalents

Sailong Pharmaceutical Group Co (SZSE:002898) Cash And Cash Equivalents : ¥56.5 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Sailong Pharmaceutical Group Co Cash And Cash Equivalents?

Sailong Pharmaceutical Group Co's quarterly cash and cash equivalents increased from Sep. 2023 (¥22.87 Mil) to Dec. 2023 (¥87.12 Mil) but then stayed the same from Dec. 2023 (¥87.12 Mil) to Mar. 2024 (¥56.55 Mil).

Sailong Pharmaceutical Group Co's annual cash and cash equivalents declined from Dec. 2021 (¥113.31 Mil) to Dec. 2022 (¥72.27 Mil) but then increased from Dec. 2022 (¥72.27 Mil) to Dec. 2023 (¥87.12 Mil).


Sailong Pharmaceutical Group Co Cash And Cash Equivalents Historical Data

The historical data trend for Sailong Pharmaceutical Group Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sailong Pharmaceutical Group Co Cash And Cash Equivalents Chart

Sailong Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.27 58.08 113.31 72.27 87.12

Sailong Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.34 58.68 22.87 87.12 56.55

Sailong Pharmaceutical Group Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Sailong Pharmaceutical Group Co  (SZSE:002898) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Sailong Pharmaceutical Group Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Sailong Pharmaceutical Group Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Sailong Pharmaceutical Group Co (SZSE:002898) Business Description

Traded in Other Exchanges
N/A
Address
No. 47, Haibin South Road, 2nd Floor, Everbright International Trade Center, Guangdong Province, Zhuhai, CHN, 519015
Zhuhai Sailong Pharmaceutical Co Ltd is the pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.
Executives
Tang Lin Director
Long Zhi Xiang Director
Deng Yong Jun Supervisors
Zhou Bei Supervisors
Li Jian Feng Directors, executives

Sailong Pharmaceutical Group Co (SZSE:002898) Headlines

No Headlines